Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1352W HIGH $17.50
Volume
1.84 K
Value Traded
1.05 K
Short % Float
0.07%
-37.86%Week
-38.73%1 Month
-53.05%3 Month
-75.33%6 Month
-99.59%5 Year
-99.94%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.13 M
EPS (TTM)
-55.32
P/E Ratio
-
Ent. Value
25.67 M
Total Shares
863.79 K
Float Shares
812.80 K
Insiders
0.00%
Institutions
0.10%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TRVN Catalyst Timeline
Dated clinical, regulatory and corporate events for Trevena, Inc.
Past FDA Catalysts and PDUFA Decisions
How TRVN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-12-31 | TRV045 Optimized | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F12 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
9
Drugs Scored
-
rNPV / MCap
Trevena, Inc. has significant pipeline risk (12/100), with 9 assets in development, but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every TRVN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TRV045 | CNS disorders | 2023-11-14 | no drug-related adverse events, no serious adverse events and no study drug-related discontinuations reportedRead More | Trevena Reports Third Quarter 2023 Results and Provides Business Update Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action andRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Shin BarryOfficer (SVP, CFO) | Sell | -31,785 873,056 held | $0.41 | 06/28/2022 |
Hedge Fund 13F Activity
Hedge Funds invested in TRVN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| NEA Management Company, LLC | 0.1 % | 4.69 M | 3.81 M |
TRVN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TRVN ranks across every disease it competes in
Competitive Position is a premium feature
See how TRVN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTRVN News
About Trevena, Inc.
Founded2014
BIOPHARMAWATCH ELITE PLUS
Trade the next TRVN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime